TYRA - Tyra Biosciences, Inc.

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).

May 21, 2026 04:00 AM • prnewswire.com

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

May 17, 2026 10:41 AM • fool.com

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 13, 2026 01:20 PM • seekingalpha.com

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - - Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 - CARLSBAD, Calif., May 13, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress.

May 13, 2026 04:00 AM • prnewswire.com

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NV TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Format: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLocation: Virtual Jefferies Global Healthcare Conference Format: Hybrid fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ETLocation: New York, NY A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences  website and will be available for replay following the event.

May 07, 2026 12:05 PM • prnewswire.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy

Apr 26, 2026 10:22 PM • defenseworld.net

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.

Apr 17, 2026 04:00 AM • prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company's

Mar 28, 2026 12:29 AM • defenseworld.net

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value rose by $10.48 million as a result of the new stake.

Mar 20, 2026 08:01 AM • fool.com

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and highlighted recent corporate progress.

Mar 02, 2026 11:05 AM • prnewswire.com

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU).

Feb 23, 2026 12:30 PM • prnewswire.com

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: 36th Annual Oppenheimer Life Sciences Healthcare Conference Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Thursday, February 26, 2026 at 12:00pm ETLocation: Virtual 46th Annual TD Cowen Healthcare Conference Format: Hybrid presentation & fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, March 4th, 2026 at 11:50am ETLocation: Boston, MA Leerink Global Healthcare Conference Format: One-on-one investor meetingsDate: March 8-11, 2026Location: Miami, FL 2026 Jefferies Biotech on the Beach Summit Format: One-on-one investor meetingsDate: March 9-11, 2026Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: One-on-one investor meetingsDate: March 10-12, 2026Location: Miami, FL A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences  website and will be available for replay following the event.

Feb 19, 2026 11:05 AM • prnewswire.com

Tyra Biosciences initiated with a Buy at Guggenheim

$54.00 (was $35.27)

Brad Canino · Guggenheim

Apr 14, 2026 04:14 PM • TheFly

Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright

$45.00 (was $27.99)

Mitchell Kapoor · H.C. Wainwright

Feb 17, 2026 06:12 AM • TheFly

Tyra Biosciences price target raised to $53 from $37 at Wedbush

$53.00 (was $30.10)

Robert Driscoll · Wedbush

Feb 13, 2026 09:03 AM • TheFly

Tyra Biosciences price target raised to $50 from $36 at Oppenheimer

$50.00 (was $31.71)

Oppenheimer

Feb 03, 2026 08:04 AM • TheFly

Tyra Biosciences initiated with an Overweight at Barclays

$59.00 (was $31.40)

Barclays

Jan 27, 2026 04:30 PM • TheFly

Tyra Biosciences price target raised to $42 from $33 at Piper Sandler

$42.00 (was $30.91)

Piper Sandler

Jan 23, 2026 06:59 AM • TheFly

Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List

$37.00 (was $22.11)

Robert Driscoll · Wedbush

Dec 16, 2025 06:20 AM • TheFly

Tyra Biosciences price target raised to $36 from $30 at Oppenheimer

$36.00 (was $12.18)

Matthew Biegler · Oppenheimer

Sep 10, 2025 07:03 AM • TheFly

Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright

$30.00 (was $16.70)

Mitchell Kapoor · H.C. Wainwright

Nov 11, 2024 07:23 AM • StreetInsider

BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy

$31.00 (was $25.98)

Jason Zemansky · Bank of America Securities

Oct 18, 2024 02:06 AM • StreetInsider

Tyra Biosciences (TYRA) PT Raised to $33 at Oppenheimer

$33.00 (was $24.64)

Matt Biegler · Oppenheimer

Sep 19, 2024 03:29 AM • StreetInsider

Piper Sandler Starts Tyra Biosciences (TYRA) at Overweight

$33.00 (was $21.57)

Christopher Raymond · Raymond James

Aug 15, 2024 12:40 AM • StreetInsider

Tyra Biosciences (TYRA) PT Raised to $25 at H.C. Wainwright

$25.00 (was $19.50)

Mitchell Kapoor · H.C. Wainwright

Aug 08, 2024 02:36 AM • StreetInsider

Tyra Biosciences (TYRA) PT Raised to $23 at H.C. Wainwright on potential upside from TYRA-300

$23.00 (was $17.37)

Mitchell Kapoor · H.C. Wainwright

Mar 20, 2024 02:39 AM • StreetInsider

Oppenheimer Initiates Coverage On Tyra Biosciences with Outperform Rating, Announces Price Target of $17

$17.00 (was $13.30)

Oppenheimer

Feb 03, 2023 12:11 AM • Benzinga